Pramiracetam

Pramiracetam

Systematic (IUPAC) name
N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide
Clinical data
Trade names	Neupramir, Pramistar, Remen
AHFS/Drugs.com	International Drug Names
Legal status	Unscheduled (US)
Routes	Oral
Pharmacokinetic data
Half-life	4.5-6.5 hours
Identifiers
CAS number	68497-62-1 N
ATC code	N06BX16
PubChem	CID 51712
ChemSpider	46801 Y
UNII	4449F8I3LE Y
ChEMBL	CHEMBL159776 Y
Chemical data
Formula	C14H27N3O2
Mol. mass	269.383 g/mol
SMILES O=C1N(CC(=O)NCCN(C(C)C)C(C)C)CCC1
InChI InChI=1S/C14H27N3O2/c1-11(2)17(12(3)4)9-7-15-13(18)10-16-8-5-6-14(16)19/h11-12H,5-10H2,1-4H3,(H,15,18) Y Key:ZULJGOSFKWFVRX-UHFFFAOYSA-N Y
N (what is this?)  (verify)

Pramiracetam is a nootropic drug derived from piracetam, and is more potent (i.e. lower dosage is used)^{[citation needed]}. It belongs to the racetam family of nootropics, and goes by the trade name Remen (Parke-Davis), Neupramir (Lusofarmaco) or Pramistar (Firma).^[1] Pramiracetam is used off-label for a wide range of applications.

History

Pramiracetam was developed by Parke-Davis in the late 1970s. The first patents for this drug appeared in 1978 (Belgium) and 1979 (US), concurrent with its first reporting of nootropic characteristics.

Side effects

Pramiracetam, like other members of the racetam family, is generally well tolerated by humans^{[citation needed]}. In a study where a small sample of human subjects with varying degrees of Alzheimer's disease were treated for 5–8 weeks, symptoms were few and mild. At relatively low dosages, a few participants reported headaches. One participant at the highest end of the dosage spectrum experienced sleepiness, decreased appetite, and dizziness^{[citation needed]}. In another study where a small sample of healthy, male human subjects were treated for 10 days, no adverse events were reported.^{[2][citation needed]}

References

External links

• http://www.biopsychiatry.com/pramiracetam.htm